Pfizer invests in, licenses four clinical-stage assets to SpringWorks

20 Aug 2020

Pfizer Inc. has created SpringWorks Therapeutics and licensed the start-up four of its rare disease programs.

Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing

Already a Biomedtracker subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com

Related Companies

Pfizer invests in, licenses four clinical-stage assets to SpringWorks

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice